Page 67 - GPD-4-1

Gene & Protein in Disease rs670 SNP in APOA1 gene

inflammatory properties of apolipoprotein A-I mimetic 34. Liang W, Huang L, Whelchel A, et al. Peroxisome
peptides. J Lipid Res. 2007;48(9):1915-1923. proliferator-activated receptor-α (PPARα) regulates wound
healing and mitochondrial metabolism in the cornea. Proc
doi: 10.1194/JLR.R700010-JLR200
Natl Acad Sci U S A. 2023;120(13):e2217576120.
24. King TW, Cochran BJ, Rye KA. ApoA-I and diabetes. doi: 10.1073/PNAS.2217576120
Arterioscler Thromb Vasc Biol. 2023;43(8):1362-1368.
35. Wang J, Zhang Y, Zhuo Q, et al. TET1 promotes fatty
doi: 10.1161/ATVBAHA.123.318267
acid oxidation and inhibits NAFLD progression by
25. Tang S, Tabet F, Cochran BJ, et al. Apolipoprotein A-I hydroxymethylation of PPARα promoter. Nutr Metab
enhances insulin-dependent and insulin-independent (Lond). 2020;17(1):1-11.
glucose uptake by skeletal muscle. Sci Rep. 2019;9(1):1-9.
doi: 10.1186/S12986-020-00466-8
doi: 10.1038/s41598-018-38014-3
36. Chen C, Li H, Song J, et al. Role of apolipoprotein A1 in
26. Cochran BJ, Bisoendial RJ, Hou L, et al. Apolipoprotein PPAR signaling pathway for nonalcoholic fatty liver disease.
A-I increases insulin secretion and production from PPAR Res. 2022;2022(1):4709300.
pancreatic β-cells via a G-protein-cAMPPKA-FoxO1- doi: 10.1155/2022/4709300
dependent mechanism. Arterioscler Thromb Vasc Biol.
2014;34(10):2261-2267. 37. Mikael LG, Pancer J, Wu Q, Rozen R. Disturbed one-carbon
metabolism causing adverse reproductive outcomes in mice
doi: 10.1161/ATVBAHA.114.304131/-/DC1 is associated with altered expression of apolipoprotein AI
27. Fung KYY, Ho TWW, Xu Z, et al. Apolipoprotein A1 and and inflammatory mediators PPARα, interferon-γ, and
high-density lipoprotein limit low-density lipoprotein interleukin-10., J Nutr. 2012;142(3):411-418.
transcytosis by binding SR-B1. J Lipid Res. 2024;65(4):100530. doi: 10.3945/JN.111.151753
doi: 10.1016/J.JLR.2024.100530 38. Yoshimura Y, Nishii S, Zaima N, Moriyama T, Kawamura Y.
28. Alicia Traughber C, Opoku E, Brubaker G, et al. Uptake of Ellagic acid improves hepatic steatosis and serum lipid
high-density lipoprotein by scavenger receptor class B type 1 composition through reduction of serum resistin levels
is associated with prostate cancer proliferation and tumor and transcriptional activation of hepatic ppara in obese,
progression in mice. J Biol Chem. 2020;295(24):8252-8261. diabetic KK-Ay mice. Biochem Biophys Res Commun.
2013;434(3):486-491.
doi: 10.1074/JBC.RA120.013694
doi: 10.1016/J.BBRC.2013.03.100
29. Oberle R, Kührer K, Österreicher T, et al. The HDL particle
composition determines its antitumor activity in pancreatic 39. Xie X, Zhang T, Zhao S, et al. Effects of n-3 polyunsaturated
cancer. Life Sci Alliance. 2022;5(9):e202101317. fatty acids high fat diet intervention on the synthesis of
hepatic high-density lipoprotein cholesterol in obesity-
doi: 10.26508/LSA.202101317 insulin resistance rats. Lipids Health Dis. 2016;15(1):1-7.
30. Masimov R, Büyükköroğlu G. HDL-chitosan nanoparticles doi: 10.1186/S12944-016-0250-3/TABLES/3
for siRNA delivery as an SR-B1 receptor targeted system.
Comb Chem High Throughput Screen. 2023;26(14):2541-2553. 40. Tayyeb JZ, Popeijus HE, Mensink RP, Konings MCJM,
Mokhtar FBA, Plat J. Short-chain fatty acids (except
doi: 10.2174/1386207326666230406124524 hexanoic acid) lower NF-kB transactivation, which rescues
31. Shah A, Rader DJ, Millar JS. The effect of PPAR-α agonism inflammation-induced decreased apolipoprotein A-I
on apolipoprotein metabolism in humans. Atherosclerosis. transcription in HepG2 cells. Int J Mol Sci. 2020;21(14):5088.
2010;210(1):35-40. doi: 10.3390/IJMS21145088
doi: 10.1016/j.atherosclerosis.2009.11.010 41. Tayyeb JZ, Popeijus HE, van de Sanden J, Zwaan W,
Mensink RP, Plat J. Effects of individual amino acids on
32. Khera AV, Millar JS, Ruotolo G, Wang MD, Rader DJ. Potent
peroxisome proliferator-activated receptor-α agonist treatment PPARα transactivation, mTORC1 activation, ApoA-I
increases cholesterol efflux capacity in humans with the transcription and pro-ApoA-I secretion. Int J Mol Sci.
metabolic syndrome. Eur Heart J. 2015;36(43):3020-3022. 2022;23(11):6071.
doi: 10.3390/IJMS23116071/S1
doi: 10.1093/EURHEARTJ/EHV291
42. Volcik KA, Nettleton JA, Ballantyne CM, Boerwinkle E.
33. Kim MK, Chae YN, Son MH, et al. PAR-5359, a well-
balanced PPARα/γ dual agonist, exhibits equivalent Peroxisome proliferator-activated receptor α genetic
antidiabetic and hypolipidemic activities in vitro and in vivo. variation interacts with n-6 and long-chain n-3 fatty acid
intake to affect total cholesterol and LDL-cholesterol
Eur J Pharmacol. 2008;595(1-3):119-125.
concentrations in the Atherosclerosis Risk in Communities
doi: 10.1016/J.EJPHAR.2008.07.066 Study. Am J Clin Nutr. 2008;87(6):1926-1931.

Volume 4 Issue 1 (2025) 9 doi: 10.36922/gpd.4354